मूलभूत आँकड़े
| CIK | 1592288 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Dimension Therapeutics, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| November 17, 2017 |
DMTX / Dimension Therapeutics, Inc. 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37601 DIMENSION THERAPEUTICS, INC. (Exact name of registrant as s |
|
| November 7, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2017 DIMENSION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37601 46-3942159 (State or Other Jurisdiction of Incorporation) ( |
|
| November 7, 2017 |
Amended and Restated Certificate of Incorporation of Dimension Therapeutics, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DIMENSION THERAPEUTICS, INC. FIRST: The name of the Corporation is Dimension Therapeutics, Inc. (the ?Corporation?). SECOND: The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, 19801. The name of its registered agent at that address is The Co |
|
| November 7, 2017 |
Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics EX-99.1 Exhibit 99.1 Contact Ultragenyx Pharmaceutical Inc. Investors & Media Danielle Keatley 415-475-6876 Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics NOVATO, Calif., November 7, 2017 ? Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) (?Ultragenyx? or the ?Company?), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare disea |
|
| November 7, 2017 |
Amended and Restated Bylaws of Dimension Therapeutics, Inc. Exhibit 3.2 BY-LAWS OF DIMENSION THERAPEUTICS, INC. A Delaware Corporation Effective November 7, 2017 TABLE OF CONTENTS Page ARTICLE I OFFICES Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings 1 Section 2. Annual Meetings 2 Section 3. Special Meetings 2 Section 4. Notice 2 Section 5. Adjournments 3 Section 6. Quorum 3 Section |
|
| November 7, 2017 |
DMTX / Dimension Therapeutics, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. |
|
| November 7, 2017 |
DMTX / Dimension Therapeutics, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on November 7, 2017 Registration No. |
|
| November 7, 2017 |
DMTX / Dimension Therapeutics, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on November 7, 2017 Registration No. |
|
| November 7, 2017 |
DMTX / Dimension Therapeutics, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on November 7, 2017 Registration No. |
|
| November 7, 2017 |
DMTX / Dimension Therapeutics, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on November 7, 2017 Registration No. |
|
| November 7, 2017 |
Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics Exhibit (a)(5)(H) Contact Ultragenyx Pharmaceutical Inc. Investors & Media Danielle Keatley 415-475-6876 Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics NOVATO, Calif., November 7, 2017 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) (Ultragenyx or the Company), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases |
|
| November 7, 2017 |
RARE / Ultragenyx Pharmaceutical Inc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) DIMENSION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. (Names of Filing Persons (Offeror)) Co |
|
| November 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37601 DIMENSION THERAPEUTICS, INC. |
|
| October 27, 2017 |
Dimension Therapeutics SC 14D9/A (AMENDMENT NO. 6) SC 14D9/A (Amendment No. 6) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. 6 Dimension Therapeutics, Inc. (Name of Subject Company) Dimension Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per |
|
| October 26, 2017 |
Ultragenyx Pharmaceutical SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) DIMENSION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. (Names of Filing Persons (Offeror)) Common Stock |
|
| October 26, 2017 |
EX-99.(A)(5)(G) Exhibit (a)(5)(G) Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx?s Acquisition of Dimension NOVATO, Calif., and CAMBRIDGE, Mass., October 26, 2017 ? Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) (?Ultragenyx? or the ?Company?), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, |
|
| October 26, 2017 |
EX-99.(A)(5)(B) 2 d472869dex99a5b.htm EX-99.(A)(5)(B) Exhibit (a)(5)(B) Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx’s Acquisition of Dimension NOVATO, Calif., and CAMBRIDGE, Mass., October 26, 2017 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) (“Ultragenyx” or the “Company”), a biopharmaceutical company focused on the development of novel produ |
|
| October 26, 2017 |
Dimension Therapeutics SC 14D9/A AMENDMENT NO. 5 SC 14D9/A Amendment No. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. 5 Dimension Therapeutics, Inc. (Name of Subject Company) Dimension Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per s |
|
| October 23, 2017 |
Ultragenyx Pharmaceutical SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) DIMENSION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. (Names of Filing Persons (Offeror)) Co |
|
| October 23, 2017 |
Dimension Therapeutics SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. |
|
| October 17, 2017 |
Ultragenyx Pharmaceutical SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) DIMENSION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. (Names of Filing Persons (Offeror)) Co |
|
| October 17, 2017 |
Dimension Therapeutics SC 14D9/A - AMENDMENT NO. 3 SC 14D9/A - Amendment No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. 3 Dimension Therapeutics, Inc. (Name of Subject Company) Dimension Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per |
|
| October 12, 2017 |
Ultragenyx Pharmaceutical SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) DIMENSION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. (Names of Filing Persons (Offeror)) Co |
|
| October 12, 2017 |
Dimension Therapeutics SC 14D9/A (AMENDMENT NO. 2) SC 14D9/A (Amendment No. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. 2 Dimension Therapeutics, Inc. (Name of Subject Company) Dimension Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per |
|
| October 11, 2017 |
Dimension Therapeutics SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. |
|
| October 11, 2017 |
Ultragenyx Pharmaceutical SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) DIMENSION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. (Names of Filing Persons (Offeror)) Co |
|
| October 10, 2017 |
Dimension Therapeutics SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 10, 2017 |
EX-99.(E)(2) 2 d469659dex99e2.htm EX-(E)(2) Exhibit (e)(2) September 19, 2017 Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato, California 94949 Attention: Karah Parschauer, General Counsel Ladies and Gentlemen: In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and you (the “Possible Transaction”), and |
|
| October 10, 2017 |
EX-99.(A)(1)(A) 2 d458405dex99a1a.htm EXHIBIT (A)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of DIMENSION THERAPEUTICS, INC. at $6.00 Net Per Share in Cash by MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN TIME, ON NOV |
|
| October 10, 2017 |
Exhibit (a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| October 10, 2017 |
Exhibit (a)(1)(E) Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of DIMENSION THERAPEUTICS, INC. |
|
| October 10, 2017 |
SCIENTIFIC ADVISORY COUNCIL AGREEMENT Exhibit (d)(3) Exhibit (d)(3) SCIENTIFIC ADVISORY COUNCIL AGREEMENT This Scientific Advisory Council Agreement, effective 1/6/2015 (this ?Agreement?) amends and restates in its entirety that certain Advisory Board Agreement dated October 1, 2013 by and between Dimension Therapeutics, Inc. |
|
| October 10, 2017 |
Ultragenyx Pharmaceutical SC TO-T SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 DIMENSION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. (Names of Filing Persons (Offeror)) Common Stock, Par Valu |
|
| October 10, 2017 |
Exhibit (a)(1)(D) Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of DIMENSION THERAPEUTICS, INC. |
|
| October 10, 2017 |
EX-99.(A)(1)(B) 3 d458405dex99a1b.htm EXHIBIT (A)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of DIMENSION THERAPEUTICS, INC. a Delaware corporation at $6.00 NET PER SHARE Pursuant to the Offer to Purchase Dated October 10, 2017 by MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE |
|
| October 10, 2017 |
EX-99.(A)(1)(C) 4 d458405dex99a1c.htm EXHIBIT (A)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of DIMENSION THERAPEUTICS, INC. a Delaware corporation at $6.00 NET PER SHARE Pursuant to the Offer to Purchase dated October 10, 2017 by MYSTIC RIVER MERGER SUB INC. a wholly-owned subsidiary of ULTRAGENYX PHARMACEUTICAL INC. THE OFFER AND WITHDRAWAL RIGHTS |
|
| October 3, 2017 |
EX-99.1 Exhibit 99.1 REGENXBIO RESPONDS TO NOTIFICATION OF A SUPERIOR PROPOSAL UNDER ITS MERGER AGREEMENT WITH DIMENSION THERAPEUTICS Company Focused on Advancing Proprietary NAV Technology Platform and Deep Gene Therapy Treatment Pipeline ROCKVILLE, MD. ? October 2, 2017 ? REGENXBIO Inc. (Nasdaq:RGNX) today announced that Dimension Therapeutics, Inc. (Nasdaq:DMTX) notified REGENXBIO that it has d |
|
| October 3, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2017 REGENXBIO INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37553 47-1851754 (State or other jurisdiction of incorporation) (Commission File |
|
| October 3, 2017 |
Dimension Therapeutics SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Dimension Therapeutics, Inc. (Name of Subject Company) Dimension Therapeutics, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 25433V105 (C |
|
| October 3, 2017 |
EX-99.2 Exhibit 99.2 External email: Dear Colleague, I am excited to inform you that Dimension Therapeutics, Inc. has entered into a definitive agreement to be acquired by Ultragenyx. The acquisition of Dimension represents the coming together of two companies with significant rare disease drug development accomplishments and a shared commitment to developing AAV gene therapy and other novel techn |
|
| October 3, 2017 |
EX-99.1 2 d469354dex991.htm EX-99.1 Exhibit 99.1 Internal announcement email: Dear Colleagues, This morning, we announced that Ultragenyx and Dimension have entered into a definitive agreement under which Ultragenyx will acquire all outstanding shares of Dimension common stock at a purchase price of $6.00 per share in cash. The boards of directors of both companies unanimously approved the transac |
|
| October 3, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2017 ULTRAGENYX PHARMACEUTICAL INC. |
|
| October 3, 2017 |
Agreement and Plan of Merger, dated October 2, 2017, among the Company, Purchaser and Dimension.* EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among: DIMENSION THERAPEUTICS, INC., a Delaware corporation; ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation; and MYSTIC RIVER MERGER SUB INC., a Delaware corporation Dated as of October 2, 2017 The Agreement and Plan of Merger (the ?Agreement?) contains representations, warranties and covenants that were made only for |
|
| October 3, 2017 |
Joint Press Release, dated October 3, 2017. EX-99.1 Exhibit 99.1 Ultragenyx to Acquire Dimension Therapeutics Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares Combined Company will be Strongly Positioned to Bring Needed New Therapies to Market NOVATO, Calif., and CAMBRIDGE, Mass., October 3, 2017 ? Ultragen |
|
| October 3, 2017 |
Dimension Therapeutics SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Dimension Therapeutics, Inc. (Name of Subject Company) Dimension Therapeutics, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 25433V105 (C |
|
| October 3, 2017 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among: DIMENSION THERAPEUTICS, INC., a Delaware corporation; ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation; and MYSTIC RIVER MERGER SUB INC., a Delaware corporation Dated as of October 2, 2017 The Agreement and Plan of Merger (the ?Agreement?) contains representations, warranties and covenants that were made only for |
|
| October 3, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 2, 2017 DIMENSION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37601 46-3942159 (State or other jurisdiction of incorporation) (C |
|
| October 3, 2017 |
EX-99.1 3 d465335dex991.htm EX-99.1 Exhibit 99.1 Ultragenyx to Acquire Dimension Therapeutics Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares Combined Company will be Strongly Positioned to Bring Needed New Therapies to Market NOVATO, Calif., and CAMBRIDGE, Mass. |
|
| October 2, 2017 |
425 Filed by REGENXBIO Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Dimension Therapeutics Inc. Commission File Number: 001-37601 REGENXBIO RESPONDS TO NOTIFICATION OF A SUPERIOR PROPOSAL UNDER ITS MERGER AGREEMENT WITH DIMENSION THERAPEUTICS Company Focused on |
|
| October 2, 2017 |
Press Release, dated October 2, 2017 EX-99.1 Exhibit 99.1 Ultragenyx Comments on Dimension Therapeutics? Announcement that Ultragenyx?s Offer is a ?Superior Proposal? NOVATO, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) ? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) (?Ultragenyx? or the ?Company?), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today commented on the determination |
|
| October 2, 2017 |
Ultragenyx Pharmaceutical FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2017 ULTRAGENYX PHARMACEUTICAL INC. |
|
| October 2, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2017 DIMENSION THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-37601 46-3942159 (State or other jurisdiction of incorporatio |
|
| October 2, 2017 |
EX-99.1 2 d468762dex991.htm EX-99.1 EXHIBIT 99.1 Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal” REGENXBIO Waives Matching Rights CAMBRIDGE, MA – October 2, 2017 – Dimension Therapeutics, Inc. (“Dimension”) (NASDAQ:DMTX) announced today that the Dimension Board of Directors (the “Dimension Board”) has dete |
|
| October 2, 2017 |
Dimension Therapeutics FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2017 DIMENSION THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-37601 46-3942159 (State or other jurisdiction of incorporatio |
|
| October 2, 2017 |
Press Release of Dimension Therapeutics, Inc. issued on October 2, 2017. EX-99.1 2 d468762dex991.htm EX-99.1 EXHIBIT 99.1 Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal” REGENXBIO Waives Matching Rights CAMBRIDGE, MA – October 2, 2017 – Dimension Therapeutics, Inc. (“Dimension”) (NASDAQ:DMTX) announced today that the Dimension Board of Directors (the “Dimension Board”) has dete |
|
| October 2, 2017 |
Dimension Therapeutics DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| September 25, 2017 |
Transcript of Conference Call on September 22, 2017 EX-99.1 2 d459947dex991.htm EX-99.1 Exhibit 99.1 RARE JPM 2017 Fall Biotech Conference Call Series September 22, 2017 – 7:30 AM PST – Conference Call Transcript Operator: Please disconnect now. At this time, all participants will be on a listen only mode for the entire duration of today’s conference. I would now like to turn the call over to Cory Kasimov, you may begin. Cory Kasimov, Senior Biotec |
|
| September 25, 2017 |
Ultragenyx Pharmaceutical FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2017 ULTRAGENYX PHARMACEUTICAL INC. |
|
| September 19, 2017 |
Dimension Therapeutics DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| September 19, 2017 |
Transcript of Investor Conference Call held by the Company on September 18, 2017 EX-99.1 Exhibit 99.1 Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash September 18, 2017 8:30 AM PST Conference Call Transcript Ryan Martins, Vice President, Strategy and Investor Relations Introduction: Participants and Agenda Good afternoon and welcome to the Ultragenyx Pharmaceutical conference call to discuss Ultragenyxs proposed offer to acquire Dimension T |
|
| September 19, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2017 ULTRAGENYX PHARMACEUTICAL INC. |
|
| September 19, 2017 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2017 DIMENSION THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-37601 46-3942159 (State or other jurisdiction of incorporation |
|
| September 19, 2017 |
EX-99.1 Exhibit 99.1 Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a ?Superior Proposal? Dimension to Begin Discussions with Ultragenyx CAMBRIDGE, Mass. ? September 19, 2017 ? Dimension Therapeutics, Inc. (NASDAQ: DMTX), a leader in discovering and developing new therapeutic products for people living with devastating r |
|
| September 19, 2017 |
Press release issued on September 19, 2017 by Dimension Therapeutics, Inc. EX-99.1 Exhibit 99.1 Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a ?Superior Proposal? Dimension to Begin Discussions with Ultragenyx CAMBRIDGE, Mass. ? September 19, 2017 ? Dimension Therapeutics, Inc. (NASDAQ: DMTX), a leader in discovering and developing new therapeutic products for people living with devastating r |
|
| September 19, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2017 DIMENSION THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-37601 46-3942159 (State or other jurisdiction of incorporation |
|
| September 18, 2017 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 18, 2017 DIMENSION THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-37601 46-3942159 (State or other jurisdiction of incorporation |
|
| September 18, 2017 |
Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx EX-99.1 2 d447300dex991.htm EX-99.1 Exhibit 99.1 Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx CAMBRIDGE, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc. (Nasdaq:DMTX) (“Dimension”), a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, today confirmed that |
|
| September 18, 2017 |
Press release issued on September 18, 2017 by Dimension Therapeutics, Inc. EX-99.1 Exhibit 99.1 Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx CAMBRIDGE, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) ? Dimension Therapeutics, Inc. (Nasdaq:DMTX) (?Dimension?), a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, today confirmed that it has received a non-bindi |
|
| September 18, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 18, 2017 DIMENSION THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-37601 46-3942159 (State or other jurisdiction of incorporation |
|
| September 18, 2017 |
Press Release, dated September 18, 2017 EX-99.1 Exhibit 99.1 Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash Proposed Combination of Complementary Rare Disease Franchises Maximizes the Ability to Bring Needed New Therapies to Market Proposal Delivers Superior Value To Dimension?s Shareholders Relative to the REGENXBIO Transaction; Provides Dimension Shareholders with Immediate Cash Premium Value of Over |
|
| September 18, 2017 |
Ultragenyx Pharmaceutical FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2017 ULTRAGENYX PHARMACEUTICAL INC. |
|
| September 18, 2017 |
Investor Presentation, dated September 18, 2017 EX-99.2 Proposal for Ultragenyx to Acquire Dimension Therapeutics September 18, 2017 Exhibit 99.2 Forward Looking Statements / Additional Information Except for the historical information contained herein, the matters set forth in this communication, including statements of anticipated changes in the business environment in which Ultragenyx operates and in Ultragenyx?s future prospects or results, |
|
| September 1, 2017 |
425 Filed by REGENXBIO Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Dimension Therapeutics Inc. Commission File Number: 001-37601 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ?2017 Thomson Reuters. All rights reserved. Republication or redis |
|
| August 31, 2017 |
Dimension Therapeutics DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| August 25, 2017 |
Dimension Therapeutics DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? De |
|
| August 25, 2017 |
EX-99.3 Corporate Presentation August 25, 2017 Exhibit 99.3 Forward-looking statements This presentation includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey |
|
| August 25, 2017 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: DIMENSION THERAPEUTICS, INC., a Delaware corporation; REGENXBIO INC., a Delaware corporation; and MUDDY CHARLES ACQUISITION CORPORATION, a Delaware corporation Dated as of August 24, 2017 The Agreement and Plan of Merger (the ?Agreement?) contains representations, warranties and covenants that were made only for purposes of the Agreemen |
|
| August 25, 2017 |
REGENXBIO to Acquire Dimension Therapeutics EX-99.2 Exhibit 99.2 REGENXBIO to Acquire Dimension Therapeutics ? Acquisition will add two lead product candidates to REGENXBIO?s metabolic disease franchise: ? DTX301 for OTC deficiency, being studied in an on-going Phase I/II clinical trial ? DTX401 for GSDIa, a late-stage preclinical candidate with an anticipated IND filing in early 2018 ? Acquisition will enhance REGENXBIO?s pipeline of gene |
|
| August 25, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2017 REGENXBIO INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37553 47-1851754 (Commission File |
|
| August 25, 2017 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: DIMENSION THERAPEUTICS, INC., a Delaware corporation; REGENXBIO INC., a Delaware corporation; and MUDDY CHARLES ACQUISITION CORPORATION, a Delaware corporation Dated as of August 24, 2017 The Agreement and Plan of Merger (the ?Agreement?) contains representations, warranties and covenants that were made only for purposes of the Agreemen |
|
| August 25, 2017 |
Dimension Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2017 DIMENSION THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-37601 46-3942159 (State or other jurisdiction of incorporatio |
|
| August 25, 2017 |
REGENXBIO to Acquire Dimension Therapeutics EX-99.1 Exhibit 99.1 REGENXBIO to Acquire Dimension Therapeutics ? Acquisition will add two lead product candidates to REGENXBIO?s metabolic disease franchise: ? DTX301 for OTC deficiency, being studied in an on-going Phase I/II clinical trial ? DTX401 for GSDIa, a late-stage preclinical candidate with an anticipated IND filing in early 2018 ? Acquisition will enhance REGENXBIO?s pipeline of gene |
|
| August 25, 2017 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: DIMENSION THERAPEUTICS, INC., a Delaware corporation; REGENXBIO INC., a Delaware corporation; and MUDDY CHARLES ACQUISITION CORPORATION, a Delaware corporation Dated as of August 24, 2017 The Agreement and Plan of Merger (the ?Agreement?) contains representations, warranties and covenants that were made only for purposes of the Agreemen |
|
| August 25, 2017 |
REGENXBIO to Acquire Dimension Therapeutics EX-99.1 Exhibit 99.1 REGENXBIO to Acquire Dimension Therapeutics ? Acquisition will add two lead product candidates to REGENXBIO?s metabolic disease franchise: ? DTX301 for OTC deficiency, being studied in an on-going Phase I/II clinical trial ? DTX401 for GSDIa, a late-stage preclinical candidate with an anticipated IND filing in early 2018 ? Acquisition will enhance REGENXBIO?s pipeline of gene |
|
| August 25, 2017 |
Dimension Therapeutics FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2017 DIMENSION THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-37601 46-3942159 (State or other jurisdiction of incorporatio |
|
| August 8, 2017 |
EX-99.1 Exhibit 99.1 Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update Initial data from Phase 1/2 clinical trial of DTX301, Dimension?s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A programs expected in early 2018 CAMBRIDGE, Mass., August 8, 2017 (GLOBE NEWSWIRE) ? Dimension The |
|
| August 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2017 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) (Commis |
|
| August 8, 2017 |
Exhibit 10.1 RIVERSIDE TECHNOLOGY CENTER SECOND LEASE AMENDMENT TO THE LEASE BETWEEN RIVERTECH ASSOCIATES II, LLC AND DIMENSION THERAPEUTICS, INC. This Second Lease Amendment (the “Second Amendment”) entered into this 28th day of April, 2017 by and between Rivertech Associates II, LLC, a Massachusetts limited liability company with a principal address c/o The Abbey Group, 177 Huntington Avenue 24t |
|
| August 8, 2017 |
DMTX / Dimension Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37601 DIMENSION THERAPEUTICS, INC. |
|
| July 24, 2017 |
EX-10.1 Exhibit 10.1 July 24, 2017 Jean Franchi 205 Pleasant Street Norwell, MA 02061 Re: Separation Agreement and Release Dear Jean: As we have discussed, your employment at Dimension Therapeutics, Inc. (the ?Company?) will end effective July 28, 2017 (the ?Date of Termination?). The letter serves as the Notice of Termination pursuant to Section 11(a) of the Employment Agreement (the ?Employment |
|
| July 24, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 21, 2017 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) |
|
| June 27, 2017 |
EX-99.1 Exhibit 99.1 Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities Initial data from Phase 1/2 clinical trial of DTX301, Dimension?s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A expected in 2018 Operating expenses reduced and cash runway extended CAMBRIDGE, Mass., June 27, 2017 (GLOBE NEWSW |
|
| June 27, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2017 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) |
|
| May 26, 2017 |
Dimension Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 25, 2017 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) |
|
| May 10, 2017 |
Dimension Therapeutics 10-Q (Quarterly Report) dmtx-10q20170331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| May 10, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2017 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) |
|
| May 10, 2017 |
EX-99.1 Exhibit 99.1 Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B Initial data from Phase 1/2 clinical trial of DTX301, Dimension?s lead AAV8 vector IMD product candidate for OTC Deficiency, expected 2H 2017 |
|
| May 10, 2017 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is between Dimension Therapeutics, Inc. (the “Company”) and Mary Thistle (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date” |
|
| May 3, 2017 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2017 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) (Commissio |
|
| April 14, 2017 |
Dimension Therapeutics DEFA14A dmtx-defa14a20170525.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 14, 2017 |
Dimension Therapeutics DEF 14A dmtx-def14a20170525.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 10, 2017 |
S-8 As filed with the U.S. Securities and Exchange Commission on March 10, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIMENSION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-3942159 (State or other jurisdiction of incorporation or organiza |
|
| March 9, 2017 |
EX-99.1 Exhibit 99.1 Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing In December, initiated Phase 1/2 clinical trial of DTX301, Dimension?s lead IMD product candidate for OTC Deficiency; Initial data expected 2H 2017 Updates interim results from Phase 1/2 clinical program for DTX101 in hemoph |
|
| March 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2017 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) |
|
| March 9, 2017 |
dmtx-10k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001- |
|
| March 9, 2017 |
Exhibit 10.18 CONFIDENTIAL EXECUTION VERSION ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 RESEARCH, COLLABORATION & LICENSE AGREEMENT DATED AS OF MAY 5, 2016 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND DIMENSION THERAPEUTICS, INC. Table of Contents Page Art |
|
| March 9, 2017 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Entity State of Incorporation or Organization Dimension Securities Corporation Massachusetts |
|
| March 9, 2017 |
SPONSORED RESEARCH AND OPTION AGREEMENT dmtx-ex1011_765.htm Exhibit 10.11 Final Execution Copy ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 SPONSORED RESEARCH AND OPTION AGREEMENT This Sponsored Research Agreement (“Agreement”), effective as of January 1, 2015 (the “Effective Date”) is made by and between The Trustees |
|
| January 31, 2017 |
Regulation FD Disclosure, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 31, 2017 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) ( |
|
| January 31, 2017 |
EX-99.1 Exhibit 99.1 Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension?s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B Evidence of High-Efficiency Liver Transduction with AAVrh10 Vector Sub-clinical, Asymptomatic Elevations of ALT Observed in 5 of 6 Patients CAMBRIDGE, Mass., January |
|
| January 31, 2017 |
EX-99.2 Exhibit 99.2 Dimension Therapeutics Dimension Therapeutics 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as ?may,? ?might,? ?will,? ?should,? ?expect,? ?plan,? ?anticipate,? ?believe,? ?estimate,? ?project,? ?intend,? ?future,? ?potential,? or ?continue,? and other similar expressio |
|
| January 20, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 18, 2017 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) ( |
|
| November 18, 2016 |
CORRESP 1 filename1.htm DIMENSION THERAPEUTICS, INC. 840 Memorial Drive Cambridge, MA 02139 November 18, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Dimension Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-214539 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated und |
|
| November 10, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2016 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporat |
|
| November 10, 2016 |
EX-99.1 Exhibit 99.1 Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results Completed patient dosing in cohort 1 and dosing cohort 2 in ongoing Phase 1/2 trial with DTX101 for hemophilia B; clinical data expected in January 2017 IND filing and initiation of Phase 1/2 study for lead Inherited Metabolic Disease (IMD) program, DTX301 for OTC deficiency, anti |
|
| November 10, 2016 |
Exhibit 4.2 DIMENSION THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [], 201[] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Truste |
|
| November 10, 2016 |
EX-4.1 Exhibit 4.1 DIMENSION THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 201[?] Senior Debt Securities TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trust |
|
| November 10, 2016 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on November 10, 2016 Registration No. |
|
| November 10, 2016 |
EX-1.2 Exhibit 1.2 DIMENSION THERAPEUTICS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement November 10, 2016 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Dimension Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), |
|
| November 10, 2016 |
Dimension Therapeutics 10-Q (Quarterly Report) dmtx-10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| August 11, 2016 |
EX-99.1 Exhibit 99.1 Dimension Therapeutics, Inc. Quality of Science. Quality of Life. August 2016 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as ?may,? ?might,? ?will,? ?should,? ?expect,? ?plan,? ?anticipate,? ?believe,? ?estimate,? ?project,? ?intend,? ?future,? ?potential,? or ?continue |
|
| August 11, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2016 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) (C |
|
| August 11, 2016 |
EX-99.1 Exhibit 99.1 Dimension Therapeutics Reports Recent Corporate Progress and Second Quarter 2016 Financial Results Ongoing Phase 1/2 trial DTX101 for hemophilia B clinical data expected later this year Lead IMD program, DTX301 for OTC deficiency, progressing toward IND filing Advancing broad inherited metabolic disease (IMD) portfolio with programs addressing citrullinemia type 1, phenylketon |
|
| August 11, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2016 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) (C |
|
| August 11, 2016 |
Dimension Therapeutics 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37601 DIMENSION THERAPEUTICS, INC. |
|
| August 11, 2016 |
Exhibit 10.1 CONFIDENTIAL EXECUTION VERSION ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 RESEARCH, COLLABORATION & LICENSE AGREEMENT DATED AS OF MAY 5, 2016 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND DIMENSION THERAPEUTICS, INC. Table of Contents Page Arti |
|
| May 20, 2016 |
S-8 As filed with the U.S. Securities and Exchange Commission on May 20, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIMENSION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-3942159 (State or other jurisdiction of incorporation or organizati |
|
| May 20, 2016 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2016 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) (Comm |
|
| May 12, 2016 |
EX-99.1 Exhibit 99.1 Dimension Therapeutics Reports Recent Corporate Progress and First Quarter 2016 Financial Results Expanded inherited metabolic disease (IMD) portfolio; New programs address citrullinemia type 1, phenylketonuria (PKU), and Wilson disease Expect to file INDs for lead IMD product candidates, DTX301 for OTC deficiency and DTX401 for GSDIa, both in second half 2016; Initiate dosing |
|
| May 12, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2016 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) (Commissi |
|
| May 12, 2016 |
Dimension Therapeutics 10-Q (Quarterly Report) dmtx-10q20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| May 6, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2016 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporation) ( |
|
| May 6, 2016 |
EX-99.1 Exhibit 99.1 Dimension Therapeutics Announces Gene Therapy Research Collaboration with the University of Pennsylvania and Expansion of Inherited Metabolic Disease Portfolio Therapeutic Programs Address Citrullinemia Type 1, Phenylketonuria, and Wilson Disease Diseases Can Have Devastating Consequences for Patients and Families, with Few Effective Treatment Options Research Collaboration Po |
|
| April 8, 2016 |
Dimension Therapeutics DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pro |
|
| April 8, 2016 |
Dimension Therapeutics DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 24, 2016 |
Dimension Therapeutics 10-K (Annual Report) dmtx-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001- |
|
| March 24, 2016 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Entity State of Incorporation or Organization Dimension Securities Corporation Massachusetts |
|
| March 24, 2016 |
Exhibit 10.15 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of August 21, 2014 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”), and DIMENSION THERAPEUTICS, INC., a Delaware corporation (“Borrower”), provides the terms o |
|
| February 12, 2016 |
Dimension Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2016 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporati |
|
| February 12, 2016 |
SECOND AMENDMENT LOAN AND SECURITY AGREEMENT EX-10.1 Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 9th day of February, 2016 by and between SILICON VALLEY BANK (?Bank?) and DIMENSION THERAPEUTICS, INC., Delaware corporation (?Borrower?) whose address is 840 Memorial Drive, Cambridge, Massachusetts 02139. RECITALS A. Bank and Borrower h |
|
| November 6, 2015 |
DMTX / Dimension Therapeutics, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 DIMENSION THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 25433V105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and |
|
| November 6, 2015 |
EX-99.1 2 ss461642ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated November 6, 2015 (the “Schedule 13D”), with respect to the Common Stock, of Dimension Therapeutics, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule |
|
| November 5, 2015 |
Dimension Therapeutics FORM S-8 Form S-8 As filed with the U.S. Securities and Exchange Commission on November 5, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIMENSION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-3942159 (State or other jurisdiction of incorporation or o |
|
| November 3, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 2, 2015 Dimension Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37601 46-3942159 (State or other jurisdiction of incorporati |
|
| November 3, 2015 |
Dimension Therapeutics Announces Expansion of Internal Research and Process Development Capabilities EX-99.1 Exhibit 99.1 Dimension Therapeutics Announces Expansion of Internal Research and Process Development Capabilities CAMBRIDGE, MASS, November 3, 2015? Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases, today announced its plans to expand the company?s internal research and process development capabi |
|
| November 3, 2015 |
EX-10.1 Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 2nd day of November, 2015, between ARE-MA REGION NO. 20, LLC, a Delaware limited liability company (?Landlord?), and DIMENSION THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: 19 Presidential Way, Woburn, Massachusetts Premises: That portion of the Building, consisting of (i) approximately 17,475 |
|
| November 2, 2015 |
DMTX / Dimension Therapeutics, Inc. / New Leaf Ventures III, L.P. - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Dimension Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 25433V105 (CUSIP Number) Craig L. Slutzkin New Leaf Venture Management III, L.L.C., Times Square Tower 7 Times Square, Suit |
|
| November 2, 2015 |
EX-99.2 CUSIP No. 25433V105 13D Page 1 of 3 Pages EXHIBIT 99.2 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints CRAIG L. SLUTZKIN as his true and lawful attorney-in-fact and agent for him and in his name, place and stead, in any and all capacities, to sign any and all documents relating to any and all Securities and Exchange Commission filings |
|
| November 2, 2015 |
EX-99.1 CUSIP No. 25433V105 13D Page 1 of 2 Pages EXHIBIT 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Dimension Therapeutics, Inc. EXECUTED this 2nd day of Nov |
|
| October 22, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
EX-24.1 2 ex-24d1.htm EX-24.1 Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer an |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 21, 2015 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Annalis Jenkins, M.B.B.S., M.R.C.P., Jean Franchi and Mary T. Thistle, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Dimension The |
|
| October 20, 2015 |
8-A12B 1 a15-1472498a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF l934 DIMENSION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-3942159 (State of incorporation or organization) (I.R.S. Employer |
|
| October 19, 2015 |
October 19, 2015 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 19, 2015 |
Goldman, Sachs & Co. 200 West Street New York, NY 10282 Citigroup Global Markets Inc. 388 Greenwich Street New York, NY 10013 October 19, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Re: DIMENSION THERAPEUTICS, INC. Registration Statement on Form S-1 (File No. 333-206911) Ladies and Gentlemen: P |
|
| October 13, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on October 13, 2015 Registration No. |
|
| September 24, 2015 |
CONFIDENTIAL TREATMENT REQUESTED BY DIMENSION THERAPEUTICS, INC. CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED FROM THE VERSION FILED VIA EDGAR. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. INFORMATION THAT WAS OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS LETTER WITH A PLACEHOLDER IDENTIFIED BY THE MARK ?[***].? September 24, 2015 VIA EDGAR AND FEDERAL |
|
| September 14, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on September 14, 2015 Registration No. |
|
| September 14, 2015 |
Goodwin Procter LLP Counsellors at Law Exchange Place Boston, MA 02109 T: 617.570.1000 F: 617.523.1231 September 14, 2015 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Re: Dimension Therapeutics, Inc. Amendment to Draft Registration Statement on Form S- |
|
| August 19, 2015 |
Goodwin Procter LLP Counsellors at Law Exchange Place Boston, MA 02109 T: 617.570.1000 F: 617.523.1231 August 19, 2015 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Re: Dimension Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted July |
|
| August 19, 2015 |
DRS/A 1 filename1.htm Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents As confidentially submitted to the Securities and Exchange Commission on August 19, 2015 as Amendment No. 1 to the Draft Registration Statement. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STAT |
|
| July 17, 2015 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on July 17, 2015 Registration No. |
